1. Skin neuroendocrinology
2. Vitamin D
3. Melanoma
4. Anticancer drugs design and testing
5. Live cell imaging
6. Immunology
7. Transplantology
8. Cell therapy
9. Modern methods of diagnosing the immune system in people after kidney transplantation
10. Search for new immunosuppressive drugs
Coordinator #1 | Coordinator #2 | Coordinator #3 | |
---|---|---|---|
Name and surname | Michał Żmijewski | Piotr Trzonkowski | Natalia Filipowicz |
Academic degree | Prof. Dr. Habil. | Prof. Dr. Habil. | Ph.D. |
Employment unit | Department of Histology | Department of Medical Immunology | International Research Agenda 3P- Medicine Laboratory |
Polish Platform of Medical Research | Dr. Habil. Michał Żmijewski | Prof. Dr. Habil. Piotr Trzonkowski | Natalia Filipowicz, Ph.D. |
michal.zmijewski@gumed.edu.pl | piotr.trzonkowski@gumed.edu.pl | natalia.filipowicz@gumed.edu.pl | |
Phone number | +48 58 349 14 37 | +48 58 349 15 39 | +48 58 349 18 52 |
1. Alternative pathways activated by Vitamin D
2. Anticancer, antifibrotic and immunomodulatory activities of vitamin D analogs
3. Hypothalamus, pituitary adrenal axis analog in the skin
4. Vitamin D deficiency in human diseases
5. Pathophysiology and treatment of skin disease
6. Assessment of the effect of Wharton’s jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases
7. Use of regulatory T cells in cell therapy of human diseases.
8. Production of cell preparations: Tregs cell vaccine – for immunosuppressive therapy in patients with graft versus host disease and Tregs vaccine against type I diabetes.
Funding agency/grant number | Title of the project | Years | |
---|---|---|---|
1. | NCN 2017/25/B/NZ3/00431 | Alternative pathways activated by vitamin D PI, 1 700 400 PLN | 2018-2022 |
2. | STRATEGMED2 /266776/17/NCBR/2015 | NCBR, “Development of novel biomarkes and innovative FGFR kinases inhibitor as an anti-cancer therapy”: Co-investigator | 2017-2020 |
3. | STRATEGMED1/233368/1/NCBR/2014 | NCBR, “Implementation of therapeutic islet transplantation in the treatment of diabetes mellitus into clinical practice.” | 2017-2020 |
4. | NCN 2011/01/B/NZ6/00322 | NCN, “Analysis of the tolerogenic properties of regulatory T lymphocytes in organ transplants in the light of their use as a therapy reducing the risk of allograft rejection.” 306 102 PLN | 2011-2016 |
Foreign partner (unit name) | Principal investigator(s) | Area of cooperation | |
---|---|---|---|
1. | University of Miami Miller School of Medicine, Miami, FL, USA | Prof. Ralf Paus | skin endocrinology |
2. | University of Alabama at Birmingham, AL, USA | Prof. Andrzej Slominski | skin endocrinology, vitamin D and its analogs, melanoma, skin stress response |
3. | University of Palermo, Palermo, Italy | Prof. Francesco Capello | Mitochondria, stress response |
4. | Southern Medical University, Guangzhou, China | Prof. Jianjun Chen | vitamin D analogs, anticancer anti-inflammatory therapy |
5. | The University of Western Australia, Perth, Australia | Prof. Robert Tuckey | vitamin D synthesis and metabolism |
1. Zmijewski MA, Carlberg C. Vitamin D receptor(s): In the nucleus but also at membranes? (2020) Exp Dermatol. Sep;29(9):876-884.
2. Piotrowska A, Wierzbicka J, Rybarczyk A, Tuckey RC, Slominski AT, Żmijewski MA (2019) Vitamin D and Its Low Calcemic Analogs Modulate Anticancer Properties of Cisplatin and Dacarbazine in the A375 Human Melanoma Cell Line. Int J Oncol. 54(4):1481-1495
3. Slominski AT, Zmijewski MA, Plonka PM, Szaflarski JP, Paus R. (2018) How ultraviolet light touches the brain and endocrine system through skin, and why. Endocrinology. 159(5):1992-2007.
p<> 4. Wierzbicka JM, Żmijewski MA, Piotrowska A, Nedoszytko B, Lange M, Tuckey RC, Slominski AT. (2016) Bioactive forms of vitamin D selectively stimulate the skin analog of the hypothalamus-pituitary-adrenal axis in human epidermal keratinocytes. Mol Cell Endocrinol. 437:312-322.
5. Piotrowska A, Wierzbicka J, Kwiatkowska K, Chodyński M, Kutner A, Żmijewski MA. (2020) Antiproliferative activity of side-chain truncated vitamin D analogs (PRI-1203 and PRI-1204) against human malignant melanoma cell lines. Eur J Pharmacol. Aug 15;881:173170.
6. Piekarska K, Urban-Wojciuk Z, Kurkowiak M, Pelikant-Malecka I, Schumacher A, Sakowska J, Spodnik J. H, Arcimowicz L, Zielinska H, Tymoniuk B, Renkielska A, Siebert J, Słominska E. Trzonkowski P. Hupp T, Marek-Trzonkowska N. (2022) Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity. Nature Communications. 13;856.
7. Chwojnicki K, Iwaszkiewicz-Grzes D, Jankowska A, Zielinski M, Lowiec P, Gliwinski M, Grzywinska M, Kowalczyk K, Konarzewska A, Glasner P, Sakowska J, Kulczycka J, Jazwinska- Curyllo A, Kubach M, Karaszewski B, Nyka W, Szurowska E, Trzonkowski P. (2021) Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study BioDrugs. 35, 47-60.
8. Trzonkowski P, Bienieszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. (2009) First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells. Clinical Immunology 133(1): 22-26.
9. Trzonkowski P, Zaucha J.M, Mysliwska J, Balon J, Szmit E, Halaburda K, Bieniaszewska M, Młotkowska M, Hellmann A, Mysliwski A. (2004) Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients. Medical Oncology. 21: 81-94
10. Trzonkowski P, Marek- Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, Wujtewicz M, Witkowski P, Mlynarski W, Balcerska A, Mysliwska J.(2012) Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children. Diabetes Care, 35(9): 1817-1820